- Study Did Not Meet Primary or Secondary Efficacy Endpoints in Hidradenitis Suppurativa- Overall Safety Profile and PK/PD Generally Consistent with Observations in Prior Studies of Zunsemetinib WAYNE ...
Appili’s ATI-1801 is a novel topical paromomycin product already evaluated in Phase 3 study for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of ...
(RTTNews) - Aclaris Therapeutics, Inc. (ACRS) Wednesday announced positive top-line results from the Phase 2b ATI-1777-AD-202 study of ATI-1777 in patients with mild to severe atopic dermatitis. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results